First-line Anti-GD2 Therapy Combined With Consolidation Chemotherapy in 3 Patients With Newly Diagnosed Metastatic Ewing Sarcoma or Ewing-like Sarcoma

Neofit J. Spasov, MD, PhD,* Frank Dombrowski, MD, PhD,† Holger N. Lode, MD, PhD,‡ Mariya Spasova, MD, PhD,* Liliya Ivanova, MD,* Ivan Mundjiev, MD,* Hassan Burmusaev, MD, PhD,* and Nikolai Siebert, PhD‡

Summary: Despite multimodal therapy, the prognosis of patients with metastatic Ewing sarcoma (ES) remains poor, with new treatments urgently needed. The disialoganglioside GD2, a well-established tumor-associated antigen, is expressed in 40% to 90% of ES cells, making it a suitable therapeutic target. Here we report 3 cases with newly diagnosed, metastatic, GD2-positive ES or Ewing-like sarcoma treated with the anti-GD2 antibody dinutuximab in addition to standard chemotherapeutic regimens. Treatment was well-tolerated, and all patients achieved complete remission, without evidence of relapse. First-line anti-GD2 immuno-therapy in patients with metastatic, GD2-positive ES or Ewing-like sarcoma represents a promising therapeutic option that warrants further clinical evaluation.

Key Words: Ewing sarcoma, immunotherapy, anti-GD2 therapy, dinutuximab beta, case report

Received for publication July 23, 2021; accepted March 31, 2022.
From the *Division of Pediatric Oncohematology, Department of Pediatrics and Medical Genetics, Medical University of Plovdiv, Plovdiv, Bulgaria; †Institute of Pathology; and ‡Department of Pediatric Hematology and Oncology, University Medicine Greifswald, Greifswald, Germany.

Writing assistance for the preparation of this manuscript was funded by EUSA Pharma. The content of the article represents the views of the authors and has not been influenced by third-party sponsorship.

© 2022 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Ewing sarcoma (ES) is a cancer of mesenchymal origin, primarily affecting bone and surrounding tissues, and is most commonly seen in children and young adults.1,2 Approximately 25% of patients are diagnosed with metastatic disease, with lung, bone and bone marrow being the most common sites of metastasis.3 The current standard of care for ES is multimodal, utilizing combination chemotherapy, radiotherapy and surgery,3 with successful management of localized disease associated with survival rates of 70% to 80%.2,3 In Europe, patients with ES are generally treated with VIDE (vincristine [V], doxorubicin [D], cyclophosphamide [C]/ifosfamide [I], etoposide [E]) induction chemotherapy, followed by local therapy, such as surgery or radiation therapy, and VAI or VAC (V, actinomycin-D, I or C) consolidation chemotherapy.3 In a recent study in patients with ES from 10 different European countries, the US regimen of compressed VDC/IE induction and IE/VC consolidation was found to be superior to the European regimen for both event-free survival and overall survival, with no excess toxicity.4 While patients with metastatic disease are generally treated with the same approach as patients with localized disease, the prognosis is much worse, with a survival probability of ~20% to 40%, dependent on metastatic sites and tumor burden.2,5 High treatment-related morbidity due to the use of aggressive front-line therapeutic regimens are additional factors that contribute to poor outcomes in these patients.2 In recent years, there have been advances in the diagnostic and molecular characterization of ES, but despite this, new targeted agents are needed to further improve patient outcomes and survival, especially in patients with metastatic disease.6,6

The disialoganglioside GD2, a glycosphingolipid involved in cell proliferation, is an established tumor-associated antigen present on multiple tumor types, including neuroblastoma, but has limited expression in normal tissues.6,9 Expression of GD2 is also highly prevalent in other pediatric solid tumors, such as ES and osteosarcoma.1 In ES, GD2 is expressed throughout various disease manifestations, including localized, disseminated or relapsed disease,10 with expression levels ranging from 40% to 90% in biopsy samples, making it a potentially useful therapeutic target in this malignancy.1,2,9

Anti-GD2 antibodies such as dinutuximab and dinutuximab beta bind to GD2 on tumor cells targeting these cells for destruction by the body's own immune system.7,9 Studies by the Children’s Oncology Group (COG) have shown that immunotherapy with dinutuximab, interleukin-2 and granulocyte-macrophage colony-stimulating factor can improve outcomes in patients with high-risk neuroblastoma when given as maintenance therapy following induction and consolidation therapy, which led to the approval of this antibody in the United States.10–12 Similarly, dinutuximab beta was approved for use in neuroblastoma in Europe, based on the positive results of the SIOPEN (International Society for Paediatric Oncology European Neuroblastoma) studies.14–17 The addition of an anti-GD2 antibody, such as
dinutuximab beta, to an existing cytotoxic regimen also has the potential to increase survival and reduce progression in other tumors with high GD2 expression levels. There are currently several ongoing clinical trials investigating anti-GD2 approaches in osteosarcoma, and the combination of dinutuximab beta and chemotherapy has also demonstrated clinical activity in an individual case with refractory ES, warranting further investigation.

In this report, we describe the disease characteristics and clinical outcomes of 2 patients with newly diagnosed, metastatic, GD2-positive ES and 1 patient with newly diagnosed, metastatic, GD2-positive Ewing-like sarcoma (ELS) treated with dinutuximab beta in addition to cytotoxic chemotherapy regimens.

MATERIALS AND METHODS

Two patients with metastatic ES and 1 with metastatic ELS attended the Department of Pediatrics and Medical Genetics, Division of Pediatric Onc hematology, Plovdiv, Bulgaria. All patients received the EWING 2012 protocol, which consists of 6 cycles of VIDE (V, 1.5 mg/m²; I, 3000 mg/m²; D, 20 mg/m²; E, 150 mg/m²) induction chemotherapy, each cycle lasting 21 days, followed by 8 cycles of VAI (V, 1.5 mg/m²; A, 0.75 mg/m²; I, 3000 mg/m²) consolidation chemotherapy, each cycle lasting 21 days. After the first VAI cycle, the patients received 1 cycle of dinutuximab beta (10 mg/m²/d over 10 d), followed by surgery and irradiation of the primary tumor (54 Gy). The remaining 4 cycles of dinutuximab beta were given after VAI cycles 3, 5 and 7, and 21 days after completion of the final VAI cycle, with radiation and surgery of metastases performed after VAI cycle 4. Dinutuximab beta, which is not currently approved for the treatment of ES, was administered under compassionate use as a last-line therapy with 3 cycles (cycle A, B, and C) of Rapid COJEC chemotherapy in cases suspicious of neuroblastoma, which was likely related to chemotherapy and resolved upon treatment with antibiotics. The side effects (all grade 1/2) associated with VAI cycles did not appear to be augmented by adding dinutuximab beta to the chemotherapy backbone. All 3 patients achieved complete remission, without evidence of relapse. As of March 2022, all patients had completed therapy, and complete response is still ongoing, with a duration ranging from 14 to 19 months (Fig. 2A).

Patient 1

A 3-year-old with torticollis, supraclavicular tumor mass and brachial plexus palsy was admitted in April 2020. The initial MRI showed a cervical paraspinal tumor mass with local spinal cord compression (Fig. 2B, left panel in top row), and a chest CT revealed a single pulmonary metastasis. Because the imaging results and the age of the patient were suspicious of neuroblastoma, the patient was started on chemotherapy with 3 cycles (cycle A, B, and C) of Rapid COJEC (cisplatin [C], vincristine [O], carboplatin [J], etoposide [E], and cyclophosphamide [C]), an induction chemotherapy usually offered to patients with high-risk neuroblastoma, which achieved an excellent response with spinal cord decompression on the following day. A biopsy of the cervical mass was performed after the first COJEC cycle, and paraspinal ES was proven after a second pathomorphological revision. The lung metastasis was also histologically confirmed after total resection (with poor surgical margins of 0.1 mm/R2).

The patient was switched to chemotherapy using the EWING 2012 protocol plus local radiotherapy of the primary tumor of 40 Gy. MRI following VIDE induction therapy and before dinutuximab beta treatment demonstrated partial response of the primary tumor (Fig. 2B, central panel in top row), and the lung metastasis was no longer evident. Total surgical removal of the residual primary tumor (R1) was performed after the first cycle of VAI and dinutuximab beta, with histology revealing complete tumor necrosis. After the surgery, the patient received the remaining VAI and dinutuximab beta cycles. MRI following treatment completion demonstrated no evidence of residual primary tumor (Fig. 2B, right panel in top row).

Patient 2

A 16-year-old who presented with sudden pain in the thoracic region of the spinal cord followed by paralysis of both legs was diagnosed with metastatic ES in March 2020. Initial CT
and MRI located a thoracic spinal tumor with total spinal compression (Fig. 2B, left panel in middle row) and a single metastasis in the lung. No bone marrow involvement or distant bone metastases were observed. The spinal cord was surgically decompressed and subtotal resection of primary tumor and pulmonary metastasis (R2) was performed. Histological analysis of resected tissue from the primary tumor and the lung metastasis confirmed the diagnosis of metastatic ES.

FIGURE 1. A, Overview of the treatment schedule. Induction chemotherapy dosing: vincristine 1.5 mg/m², ifosfamide 3000 mg/m², doxorubicin 20 mg/m², etoposide 150 mg/m², actinomycin-D 0.75 mg/m² (VIDE). Consolidation chemotherapy dosing: vincristine 1.5 mg/m², actinomycin-D 0.75 mg/m², ifosfamide 3000 mg/m² (VAI). Dinutuximab beta was started on the first day after the completion of the VAI cycles 1, 3, 5, and 7, and 21 days after completion of VAI cycle 8. Granulocyte colony-stimulating factor was given simultaneously with dinutuximab beta, and was discontinued when granulocytes were >500/µL. B, CD99 expression in paraffin-embedded tumor specimens from all 3 patients. C, GD2 expression in paraffin-embedded tumor specimens of the 3 patients with ES and a patient with neuroblastoma (included as positive control). Tumor cells were confirmed by H&E staining (left panels) and GD2 expression was shown by immunohistochemistry using murine anti-GD2 antibody 14G2a (right panels; brown). GD2 indicates disialoganglioside 2; H&E, hematoxylin and eosin; VAI, vincristine, actinomycin-D, ifosfamide; VIDE, vincristine, ifosfamide, doxorubicin, etoposide.
Metastases were also reduced in size after the tumor was metabolically active but reduced in size. Pulmonary positron emission tomography CT showed that the primary after completion of VIDE therapy revealed a substantial nearly completely regressed after the third cycle of VIDE. MRI demonstrated a tumor mass encompassing the ventral, and whole lung irradiation was performed. The patient continued to receive the remaining cycles of consolidation therapy with VAI and dinutuximab beta. CT following treatment completion revealed no evidence of residual primary tumor.

**DISCUSSION**

The new treatment approach combining dinutuximab beta with a cytotoxic chemotherapy regimen was well-tolerated in all 3 patients with metastatic, GD2-positive ES or ELS, with no severe side effects reported. All patients achieved complete remission of the primary tumor and metastases, with an ongoing duration of response ranging from 14 to 19 months as of March 2022. One of the patients had no primary tumor after VIDE therapy, while the other 2 patients exhibited remaining primary tumors after induction, both of which demonstrated complete necrosis following 1 cycle of VAI and dinutuximab beta.

Targeting GD2 with dinutuximab beta is the standard of care approach to treating high-risk neuroblastoma in the maintenance setting in Europe and has significant added value in the care approach to treating high-risk neuroblastoma in the maintenance setting in Europe and has significant added value in the treatment of high-risk neuroblastoma.
suggests that early use of anti-GD2 immunotherapy—during or after induction chemotherapy and before surgery—may also be beneficial in patients with high-risk neuroblastoma,\textsuperscript{20–23} including those with relapsed/refractory disease.\textsuperscript{24,25} The FDA-approved anti-GD2 antibody dinutuximab demonstrated significant anti-tumor activity in children with refractory or relapsed neuroblastoma when used in combination with chemotherapy,\textsuperscript{24,25} and pediatric dosing strategies, schedules and toxicities are well-documented with this therapy combination.\textsuperscript{18} Clinical trials investigating dinutuximab beta in combination with chemotherapy in patients with relapsed/refractory neuroblastoma are currently ongoing.

High GD2 expression levels in ES and ELS indicate that these tumors could also be successfully targeted with GD2-directed therapy, and in a recent case report, dinutuximab beta given alongside chemotherapy has demonstrated clinical activity in a patient with refractory ES.\textsuperscript{8} Our findings provide further evidence that anti-GD2 immunotherapy added to chemotherapy might be a suitable treatment option for patients with metastatic ES or ELS.

**FIGURE 2.** A, Duration of response from diagnosis. PR occurred within 3 to 4 months of diagnosis and CR after another 2 to 4 months. Responses are still ongoing as of March 2022. B, MRI scans of the primary tumor for patient 1 (top row), patient 2 (middle row) and patient 3 (bottom row) at diagnosis (left panels), after VIDE therapy and before dinutuximab beta (central panels) and after dinutuximab beta (right panels). Please note that the MRI in the right panel for patient 3 was performed after the first cycle of dinutuximab beta but before surgery. CR indicates complete response; MRI, magnetic resonance imaging; PR, partial response; VIDE, vincristine, ifosfamide, doxorubicine, etoposide.
While dinutuximab beta is approved for use as maintenance therapy in neuroblastoma,17 it is not currently indicated for the treatment of ES or ELS. However, based on the promising results reported with the use of early immunotherapy and a combination of immunotherapy and chemotherapy in neuroblastoma,20–25 we treated our patients with GD2-positive ES and ELS in a similar way. We combined dinutuximab beta treatment with consolidation therapy, with 1 cycle of dinutuximab beta being administered before surgery and the remaining cycles during the postoperative phase, in between VAI cycles. Administering the remaining cycles during rather than postconsolidation ensures that the period without immunotherapy is minimized, which may avoid possible drug resistance.

While our case report has several limitations, including the small patient number, the short follow-up duration and its retrospective nature, our findings, in addition to previous results achieved with anti-GD2 therapy in neuroblastoma, suggest that a treatment approach combining anti-GD2 immunotherapy and chemotherapy might be worth exploring in a wider clinical study in patients with ES and/or ELS, especially those with metastatic disease.

The high expression of GD2 in some ES/ELS biopsies may be an important factor to aid in treatment selection and the journey toward a personalized medicine approach for these patients.9 We were able to confirm GD2 expression in the biopsies from our patients before dinutuximab beta treatment. However, identification of GD2 on cells using immunohistochemistry has been inconsistent, and a standardized approach to detecting this marker is needed to be able to routinely categorize tumors based on GD2 expression.18

Overall, our findings suggest that anti-GD2 immunotherapy combined with chemotherapy in patients with newly diagnosed, metastatic ES or ELS represents a promising therapeutic option that warrants further clinical evaluation.

ACKNOWLEDGMENTS

The authors thank Katrin Male from mXn Medical Communications funded by EUSA Pharma for providing editorial support.

REFERENCES

1. Biermann JS, Chow W, Reed DR, et al. NCCN Guidelines insights: bone cancer, version 2.2017. J Natl Compr Canc Netw. 2017;15:155–167.
2. Casey DL, Lin TY, Cheung NV. Exploiting signaling pathways and immune targets beyond the standard of care for Ewing sarcoma. Front Oncol. 2019;9:537.
3. Strauss SJ, Frezza AM, Abecasis N, et al. Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up. Eur J Oncol. 2021;32:1520–1536.
4. Brennan B, Kirton L, Marc-Beard P, et al. Comparison of two chemotherapy regimens in Ewing sarcoma (ES): Overall and subgroup results of the Euro Ewing 2012 randomized trial (EE2012). J Clin Oncol. 2020;38(suppl):11:500.
5. Henrich IC, Young R, Quick L, et al. USP6 confers sensitivity to IFN-β-mediated apoptosis through modulation of TRAIL signaling in Ewing sarcoma. Mol Cancer Res. 2018;16:1834–1843.
6. Birdi HK, Jirovec A, Cortés-Kaplan S, et al. Immunotherapy for sarcomas: new frontiers and unveiled opportunities. J Immunother Cancer. 2021;9:e001580.
7. Perez Horta Z, Goldberg JL, Sondel PM. Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapy. Immunotherapy. 2016;8:1097–1117.
8. Wingert A, El Malik K, Sandhoff R, et al. Exploiting gangliosides for the therapy of Ewing’s sarcoma and HJ K27M-mutant diffuse midline glioma. Cancers. 2021;13:520.
9. Nazha B, Inal C, Owonikoko TK. Disialoganglioside GD2 expression in solid tumors and role as a target for cancer therapy. Front Oncol. 2020;10:1000.
10. Kailayangiri S, Altavera B, Meltzer J, et al. The ganglioside antigen G(D2) is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting. Br J Cancer. 2012;106:1123–1133.
11. Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010;363:1324–1334.
12. FDA. Dinutuximab prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125516s000lbl.pdf. Accessed March 2022.
13. Yu AL, Gilman AL, Ozkaynak MF, et al. Long-term follow-up of a phase III study of ch14.18 (dinutuximab) + cytokine immunotherapy in children with high-risk neuroblastoma: COG study ANBL0032. Clin Cancer Res. 2021;27:2179–2189.
14. Ladenstein R, Pötschger U, Calveau-Couanet D, et al. Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19:1617–1629.
15. Ladenstein R, Pötschger U, Calveau-Couanet D, et al. Investigation of the role of dinutuximab beta-based immunotherapy in the SIOPEN high-risk neuroblastoma 1 trial (HR-NBL1). Cancers (Basel). 2020;12:309.
16. Ladenstein RL, Pötschger U, Calveau-Couanet D, et al. Randomization of dose-reduced subcutaneous interleukin-2 (scIL2) in maintenance immunotherapy (IT) with anti-GD2 antibody dinutuximab beta (DB) long-term infusion (LTI) in front-line high-risk neuroblastoma patients: Early results from the HR-NBL1/SIOPEN trial. J Clin Oncol. 2019;37(suppl):10013.
17. EMA. Qarziba (dinutuximab beta) summary of product characteristics. Available at: https://www.medicines.org.uk/emc/product/9441/smpc#grey. Accessed March 2022.
18. Bailey K, Cost C, Davis I, et al. Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Children’s Oncology Group (COG) New Agents for Ewing Sarcoma Task Force. F1000Res. 2019;8:493.
19. Wienie J, Dierselmans MP, Tytgat GAM, et al. The immune landscape of neuroblastoma: challenges and opportunities for novel therapeutic strategies in pediatric oncology. Eur J Cancer. 2021;144:123–150.
20. Spasov N, Spasova M. Early use of dinutuximab beta in patients with high-risk neuroblastoma. Case Rep Pediatr. 2021;2021:6610955.
21. Garrett J, Shultkin BL, Helwig S, et al. Induction chemotherapy with an Anti-GD2 monoclonal antibody (dinutuximab) and cytokines in children with newly diagnosed high-risk neuroblastoma: a case series. J Pediatr Hematol Oncol. 2021;43:e692–e696.
22. Furman WL, Federico SM, McCarville MB, et al. A phase II trial of Hu14.18K322A in combination with induction chemotherapy in children with newly diagnosed high-risk neuroblastoma. Clin Res. 2019;25:6320–6328.
23. Furman WL, McCarville MB, Shultkin BL, et al. Improved outcome in children with newly diagnosed high-risk neuroblastoma treated with chemoinmunotherapy: updated results of a phase II study using hu14.18K322A. J Clin Oncol. 2022;40:335–344.
24. Mody R, Naranjo A, Van Ryn C, et al. Irinotecan-temozolomide with temozolomide or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial. Lancet Oncol. 2017;18:946–957.
25. Mody R, Yu AL, Naranjo A, et al. Irinotecan, temozolomide, and dinutuximab with GM-CSF in children with refractory or relapsed neuroblastoma: a report from the Children’s Oncology Group. J Clin Oncol. 2020;38:2160–2169.